An ERK1/2-driven RNA-binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene

EMBO J. 2023 Jun 1;42(11):e110902. doi: 10.15252/embj.2022110902. Epub 2023 Apr 11.

Abstract

Oncogenic RAS signaling reprograms gene expression through both transcriptional and post-transcriptional mechanisms. While transcriptional regulation downstream of RAS is relatively well characterized, how RAS post-transcriptionally modulates gene expression to promote malignancy remains largely unclear. Using quantitative RNA interactome capture analysis, we here reveal that oncogenic RAS signaling reshapes the RNA-bound proteomic landscape of pancreatic cancer cells, with a network of nuclear proteins centered around nucleolin displaying enhanced RNA-binding activity. We show that nucleolin is phosphorylated downstream of RAS, which increases its binding to pre-ribosomal RNA (rRNA), boosts rRNA production, and promotes ribosome biogenesis. This nucleolin-dependent enhancement of ribosome biogenesis is crucial for RAS-induced pancreatic cancer cell proliferation and can be targeted therapeutically to inhibit tumor growth. Our results reveal that oncogenic RAS signaling drives ribosome biogenesis by regulating the RNA-binding activity of nucleolin and highlight a crucial role for this mechanism in RAS-mediated tumorigenesis.

Keywords: Nucleolin; RAS; RNA-binding proteins; pancreatic ductal adenocarcinoma; ribosome biogenesis.

MeSH terms

  • Cell Transformation, Neoplastic / genetics
  • Genes, ras*
  • Humans
  • MAP Kinase Signaling System
  • Nucleolin
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / metabolism
  • Phosphoproteins / metabolism
  • Proteomics
  • RNA / metabolism
  • RNA, Ribosomal / metabolism
  • Ribosomes / genetics
  • Ribosomes / metabolism

Substances

  • Phosphoproteins
  • RNA, Ribosomal
  • RNA